Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.

Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ.

CA Cancer J Clin. 2010 May-Jun;60(3):166-93. doi: 10.3322/caac.20069. Review.

2.

Molecular advances of brain tumors in radiation oncology.

Noda SE, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, Chakravarti A.

Semin Radiat Oncol. 2009 Jul;19(3):171-8. doi: 10.1016/j.semradonc.2009.02.005. Review.

PMID:
19464632
3.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
4.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
5.

Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.

Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK.

J Clin Oncol. 2015 Apr 1;33(10):1197-213. doi: 10.1200/JCO.2014.55.9575. Epub 2015 Feb 23.

6.

Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.

Onishi M, Kurozumi K, Ichikawa T, Date I.

Neurol Med Chir (Tokyo). 2013;53(11):755-63. Epub 2013 Oct 25. Review.

7.

Angiogenesis inhibitors in tackling recurrent glioblastoma.

Hundsberger T, Reardon DA, Wen PY.

Expert Rev Anticancer Ther. 2017 Jun;17(6):507-515. doi: 10.1080/14737140.2017.1322903. Epub 2017 May 2. Review.

PMID:
28438066
8.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review.

PMID:
25242542
9.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

10.

New treatment strategies for malignant gliomas.

Sathornsumetee S, Rich JN.

Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104. Review.

PMID:
16831080
11.

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

Niyazi M, Harter PN, Hattingen E, Rottler M, von Baumgarten L, Proescholdt M, Belka C, Lauber K, Mittelbronn M.

Oncotarget. 2016 Jan 19;7(3):2313-28. doi: 10.18632/oncotarget.6320. Review.

12.

Recent advances in targeted therapy for glioblastoma.

Mittal S, Pradhan S, Srivastava T.

Expert Rev Neurother. 2015;15(8):935-46. doi: 10.1586/14737175.2015.1061934. Epub 2015 Jun 28. Review.

PMID:
26118735
13.

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24. doi: 10.1016/j.ijrobp.2010.12.074. Epub 2011 Apr 12.

14.

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

Polivka J Jr, Polivka J, Holubec L, Kubikova T, Priban V, Hes O, Pivovarcikova K, Treskova I.

Anticancer Res. 2017 Jan;37(1):21-33. Review.

PMID:
28011470
15.

Resistance to antiangiogenic therapies.

Bartolotti M, Franceschi E, Poggi R, Tosoni A, Di Battista M, Brandes AA.

Future Oncol. 2014 Jun;10(8):1417-25. doi: 10.2217/fon.14.57. Review.

PMID:
25052752
16.

[Anti-angiogenic strategies in glioblastoma].

Guillamo JS.

Rev Neurol (Paris). 2011 Oct;167(10):662-7. doi: 10.1016/j.neurol.2011.07.008. Epub 2011 Sep 1. Review. French.

PMID:
21889779
17.

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ.

Expert Opin Biol Ther. 2008 Apr;8(4):541-53. doi: 10.1517/14712598.8.4.541 . Review.

18.

MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.

Jalali S, Chung C, Foltz W, Burrell K, Singh S, Hill R, Zadeh G.

Neuro Oncol. 2014 Jun;16(6):868-79. doi: 10.1093/neuonc/nou040. Epub 2014 Apr 23.

19.

Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma.

Saito N, Aoki K, Hirai N, Fujita S, Iwama J, Hiramoto Y, Ishii M, Sato K, Nakayama H, Harashina J, Hayashi M, Izukura H, Kimura H, Ito K, Sakurai T, Yokouchi Y, Oharazeki T, Takahashi K, Iwabuchi S.

Brain Tumor Pathol. 2015 Jul;32(3):176-83. doi: 10.1007/s10014-015-0215-7. Epub 2015 Feb 10.

PMID:
25665548
20.

Targeting ErbB receptors in high-grade glioma.

Berezowska S, Schlegel J.

Curr Pharm Des. 2011;17(23):2468-87. Review.

PMID:
21827413

Supplemental Content

Support Center